Live Breaking News & Updates on Prostate specific membrane antigen targeted

Stay updated with breaking news from Prostate specific membrane antigen targeted. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Munich , Bayern , Germany , Milan , Lombardia , Italy , United-kingdom , United-states , Mike-beyer , Bruce-spottiswoode , Scintomics-gmb , David-gauden

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Germany , Munich , Bayern , United-states , Milan , Lombardia , Italy , Siemens-healthineers , Scintomics-gmb , David-gauden , Bruce-spottiswoode , Technical-university-of-munich

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

177Lutetium-labeled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical

United-states , Munich , Bayern , Germany , San-diego , California , American , Davide-gauden , Scintomics-gmb , Technical-university-of-munich , American-association-for-cancer-research

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1

United-states , Germany , German , Constantin-lapa , David-gauden , Department-of-nuclear-medicine , University-hospital-augsburg , Journal-of-nuclear-medicine , Drug-administration , University-hospital , Blue-earth-therapeutics , Efficacy-data

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 1

– First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1 –– 177Lutetium-labeled radiohybrid (rh) Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is now in clinical development as a highly optimized, next ge...

United-kingdom , Germany , Italy , Milan , Lombardia , United-states , German , Mike-beyer , Priscilla-harlan , David-gauden , Clare-gidley , Constantin-lapa

Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU

Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Italy , Germany , United-kingdom , Munich , Bayern , Milan , Lombardia , Clare-gidley , Santa-monica , Davide-gauden , Stefan-klotter , Priscilla-harlan

Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU

Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Munich , Bayern , Germany , Italy , Milan , Lombardia , Santa-monica , Scintomics-gmb , Przemyslaw-twardowski , Davide-gauden , Study-group , Drug-administration

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Munich , Bayern , Germany , Italy , Sichuan , Gansu , China , Beijing , Shanghai , United-states , United-kingdom , Milan

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer P

− Agreement with Sinotau Pharmaceutical Group part of Company’s global strategy to increase clinician and patient access to innovative diagnostic imaging agent –OXFORD, England & MONROE TOWNSHIP, N.J.--(BUSINESS WIRE)--Blue Earth Diagnostics Ltd, a Bracco company and recognised leader in the development and commerci...

United-kingdom , Milan , Lombardia , Italy , Guangdong , Jilin , China , United-states , Shanghai , Munich , Bayern , Germany

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Sub-group analysis from Blue Earth Diagnostics’ Phase 3 LIGHTHOUSE trial highlights POSLUMA utility to guide treatment selection and potentially avoid futile surgery

Germany , Munich , Bayern , Davide-gauden , Garya-ulaner , Scintomics-gmb , Philliph-kuo , Los-angeles , University-of-arizona , Study-group , Drug-administration , University-of-southern-california